{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:48:20Z","timestamp":1782708500465,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15684-1","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T02:27:08Z","timestamp":1770172028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic stratification in gastric cancer with peritoneal metastasis: tumor biology and diagnostic modality as a surrogate for disease burden"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-3926","authenticated-orcid":false,"given":"K\u00fcbra","family":"Canaslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkut","family":"Demirciler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"\u00c7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koray","family":"Atila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Ata\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lhan","family":"\u00d6ztop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"3","key":"15684_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"15684_CR2","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3390\/cancers15061777","volume":"15","author":"I Manzanedo","year":"2023","unstructured":"Manzanedo I, Pereira F, P\u00e9rez-Viejo E, Serrano \u00c1. Gastric cancer with peritoneal metastases: current status and prospects for treatment. Cancers (Basel). 2023;15(6):1777. https:\/\/doi.org\/10.3390\/cancers15061777.","journal-title":"Cancers (Basel)"},{"key":"15684_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.21037\/dmr-21-94","volume":"5","author":"BL Green","year":"2022","unstructured":"Green BL, Davis JL. Gastric adenocarcinoma peritoneal carcinomatosis: a narrative review. Dig Med Res. 2022;5:37. https:\/\/doi.org\/10.21037\/dmr-21-94.","journal-title":"Dig Med Res"},{"issue":"21","key":"15684_CR4","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.3390\/jcm10214882","volume":"10","author":"A Rijken","year":"2021","unstructured":"Rijken A, Lurvink RJ, Luyer MDP, Nieuwenhuijzen GAP, van Erning FN, van Sandick JW, et al. The burden of peritoneal metastases from gastric cancer: A systematic review on the Incidence, risk factors and survival. J Clin Med. 2021;10(21):4882. https:\/\/doi.org\/10.3390\/jcm10214882.","journal-title":"J Clin Med"},{"issue":"1","key":"15684_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12885-023-10537-7","volume":"23","author":"J Yang","year":"2023","unstructured":"Yang J, Su H, Chen T, Chen X, Chen H, Li G, Yu J. Development and validation of nomogram of peritoneal metastasis in gastric cancer based on simplified clinicopathological features and serum tumor markers. BMC Cancer. 2023;23(1):64. https:\/\/doi.org\/10.1186\/s12885-023-10537-7.","journal-title":"BMC Cancer"},{"issue":"6","key":"15684_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1373\/clinchem.2009.133124","volume":"56","author":"CM Sturgeon","year":"2010","unstructured":"Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, et al. National academy of clinical biochemistry. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010;56(6):e1\u201348. https:\/\/doi.org\/10.1373\/clinchem.2009.133124.","journal-title":"Clin Chem"},{"key":"15684_CR7","doi-asserted-by":"publisher","first-page":"103109","DOI":"10.1016\/j.eclinm.2025.103109","volume":"81","author":"NAD Guchelaar","year":"2025","unstructured":"Guchelaar NAD, de Neijs MJ, Noordman BJ, Graaf HEC, van Hellemond IEG, van der Sluis PC, et al. The prognostic value of peritoneal metastases in patients with gastric cancer: a nationwide population-based study. EClinicalMedicine. 2025;81:103109. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103109.","journal-title":"EClinicalMedicine"},{"issue":"10294","key":"15684_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"10418","key":"15684_CR9","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197\u2013208. https:\/\/doi.org\/10.1016\/S0140-6736(23)02033-0.","journal-title":"Lancet"},{"issue":"11","key":"15684_CR10","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6.","journal-title":"Lancet Oncol"},{"issue":"6","key":"15684_CR11","doi-asserted-by":"publisher","first-page":"570","DOI":"10.21147\/j.issn.1000-9604.2016.06.03","volume":"28","author":"R Nie","year":"2016","unstructured":"Nie R, Yuan S, Chen S, Chen X, Chen Y, Zhu B, et al. Prognostic nutritional index is an independent prognostic factor for gastric cancer patients with peritoneal dissemination. Chin J Cancer Res. 2016;28(6):570\u20138. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2016.06.03.","journal-title":"Chin J Cancer Res"},{"issue":"9","key":"15684_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4251\/wjgo.v8.i9.673","volume":"8","author":"WJ Shi","year":"2016","unstructured":"Shi WJ, Gao JB. Molecular mechanisms of chemoresistance in gastric cancer. World J Gastrointest Oncol. 2016;8(9):673\u201381. https:\/\/doi.org\/10.4251\/wjgo.v8.i9.673.","journal-title":"World J Gastrointest Oncol"},{"key":"15684_CR13","doi-asserted-by":"publisher","first-page":"175883592513630","DOI":"10.1177\/17588359251363057","volume":"17","author":"Y Narita","year":"2025","unstructured":"Narita Y, Muro K. Systemic therapy strategies for elderly patients with gastric cancer. Ther Adv Med Oncol. 2025;17:17588359251363057. https:\/\/doi.org\/10.1177\/17588359251363057. Published 2025 Aug 16.","journal-title":"Ther Adv Med Oncol"},{"key":"15684_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53\u201363. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_4.","journal-title":"Cancer Treat Res"},{"issue":"9","key":"15684_CR15","doi-asserted-by":"publisher","first-page":"oyaf219","DOI":"10.1093\/oncolo\/oyaf219","volume":"30","author":"MW Tops-Welten","year":"2025","unstructured":"Tops-Welten MW, Galanos LJK, Creemers GJ, Luyer MDP, De Hingh IHJT, van Hellemond IEG. Gastrointestinal canceremerging treatment modalities for gastric cancer with peritoneal metastases: a systematic review. Oncologist. 2025;30(9):oyaf219. https:\/\/doi.org\/10.1093\/oncolo\/oyaf219.","journal-title":"Oncologist"},{"issue":"Suppl 1","key":"15684_CR16","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.21037\/jgo-20-232","volume":"12","author":"I Manzanedo","year":"2021","unstructured":"Manzanedo I, Pereira F, Serrano \u00c1, P\u00e9rez-Viejo E. Review of management and treatment of peritoneal metastases from gastric cancer origin. J Gastrointest Oncol. 2021;12(Suppl 1):S20\u20139. https:\/\/doi.org\/10.21037\/jgo-20-232.","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"15684_CR17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10120-021-01160-1","volume":"24","author":"WJ Koemans","year":"2021","unstructured":"Koemans WJ, Lurvink RJ, Grootscholten C, Verhoeven RHA, de Hingh IH, van Sandick JW. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort. Gastric Cancer. 2021;24(4):800\u20139. https:\/\/doi.org\/10.1007\/s10120-021-01160-1.","journal-title":"Gastric Cancer"},{"issue":"6","key":"15684_CR18","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1007\/s00330-019-06524-x","volume":"30","author":"I van \u2019t Sant","year":"2020","unstructured":"van \u2018t Sant I, Engbersen MP, Bhairosing PA, Lambregts DMJ, Beets-Tan RGH, van Driel WJ, et al. Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis. EurRadiol. 2020;30(6):3101\u201312. https:\/\/doi.org\/10.1007\/s00330-019-06524-x.","journal-title":"EurRadiol"},{"issue":"13","key":"15684_CR19","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1245\/s10434-016-5409-7","volume":"23","author":"N Ikoma","year":"2016","unstructured":"Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, et al. Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. 2016;23(13):4332\u20137. https:\/\/doi.org\/10.1245\/s10434-016-5409-7.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"15684_CR20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3390\/cancers14030570","volume":"14","author":"BJ Sun","year":"2022","unstructured":"Sun BJ, Lee B. Review of regional therapies for gastric cancer with peritoneal metastases. Cancers (Basel). 2022;14(3):570. https:\/\/doi.org\/10.3390\/cancers14030570. Published 2022 Jan 23.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"15684_CR21","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3390\/cancers16101929","volume":"16","author":"L Langellotti","year":"2024","unstructured":"Langellotti L, Fiorillo C, D\u2019Annibale G, Panza E, Pacelli F, Alfieri S, et al. Efficacy of cytoreductive surgery (CRS) + HIPEC in gastric cancer with peritoneal metastasis: systematic review and Meta-Analysis. Cancers (Basel). 2024;16(10):1929. https:\/\/doi.org\/10.3390\/cancers16101929.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"15684_CR22","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.gassur.2024.04.007","volume":"28","author":"M Stefano","year":"2024","unstructured":"Stefano M, Perrina D, Vallicelli C, Ansaloni L, Fugazzola P, Coccolini F, et al. Prophylaxis and treatment of peritoneal carcinomatosis of gastric origin using hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis of randomized trials. J Gastrointest Surg. 2024;28(7):1185\u201393. https:\/\/doi.org\/10.1016\/j.gassur.2024.04.007.","journal-title":"J Gastrointest Surg"},{"issue":"3","key":"15684_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.5230\/jgc.2025.25.e36","volume":"25","author":"HI Kim","year":"2025","unstructured":"Kim HI, Badgwell BD. Peritoneal oligometastasis in gastric cancer: diagnostic Strategies, patient Selection, and emerging therapeutic approaches. J Gastric Cancer. 2025;25(3):409\u201323. https:\/\/doi.org\/10.5230\/jgc.2025.25.e36.","journal-title":"J Gastric Cancer"},{"issue":"6","key":"15684_CR24","doi-asserted-by":"publisher","first-page":"109731","DOI":"10.1016\/j.ejso.2025.109731","volume":"51","author":"A Mariani","year":"2025","unstructured":"Mariani A, Triantafyllou E, Kepenekian V, Zaanan A, Glehen O, Karoui M. Management of peritoneal gastric metastasis: an update. Eur J Surg Oncol. 2025;51(6):109731. https:\/\/doi.org\/10.1016\/j.ejso.2025.109731.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"15684_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12885-021-08058-2","volume":"21","author":"TH Kim","year":"2021","unstructured":"Kim TH, Do Cho H, Choi YW, Lee HW, Kang SY, Jeong GS, et al. Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data. BMC Cancer. 2021;21(1):325. https:\/\/doi.org\/10.1186\/s12885-021-08058-2.","journal-title":"BMC Cancer"},{"issue":"9","key":"15684_CR26","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.3390\/medicina61091675","volume":"61","author":"M Uzun","year":"2025","unstructured":"Uzun M, Gokcek S, Kilinc M, Ekinci F, Avci T, Erdogan AP, et al. The effect of HER2 status on gastric cancer survival and the clinical implications of the HER2-Low definition: A retrospective study. Med (Kaunas). 2025;61(9):1675. https:\/\/doi.org\/10.3390\/medicina61091675.","journal-title":"Med (Kaunas)"},{"issue":"9742","key":"15684_CR27","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. ToGA trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"issue":"11","key":"15684_CR28","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.3390\/biomedicines12112584","volume":"12","author":"M B\u0105k","year":"2024","unstructured":"B\u0105k M, Wojciech M, Pielech A, Holka S, Zawadzki M, Murawa D. The advancement stage of gastric cancer and the levels of CEA and Ca19-9 in serum and peritoneal lavage. Biomedicines. 2024;12(11):2584. https:\/\/doi.org\/10.3390\/biomedicines12112584. Published 2024 Nov 12.","journal-title":"Biomedicines"},{"key":"15684_CR29","doi-asserted-by":"publisher","first-page":"1418978","DOI":"10.1155\/2020\/1418978","volume":"2020","author":"C Yang","year":"2020","unstructured":"Yang C, Yang Y, Huang X, Li H, Cheng H, Tong S, et al. A nomogram based on clinicopathologic features and preoperative hematology parameters to predict occult peritoneal metastasis of gastric cancer: A Single-Center retrospective study. Dis Markers. 2020;2020:1418978. https:\/\/doi.org\/10.1155\/2020\/1418978.","journal-title":"Dis Markers"},{"key":"15684_CR30","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3389\/fonc.2019.01159","volume":"9","author":"C Huang","year":"2019","unstructured":"Huang C, Liu Z, Xiao L, Xia Y, Huang J, Luo H, et al. Clinical significance of serum CA125, CA19-9, CA72-4, and Fibrinogen-to-Lymphocyte ratio in gastric cancer with peritoneal dissemination. Front Oncol. 2019;9:1159. https:\/\/doi.org\/10.3389\/fonc.2019.01159.","journal-title":"Front Oncol"},{"issue":"2","key":"15684_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3978\/j.issn.2078-6891.2011.021","volume":"3","author":"UK Ballehaninna","year":"2012","unstructured":"Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19\u2009\u2013\u20099 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012;3(2):105\u201319. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2011.021.","journal-title":"J Gastrointest Oncol"},{"key":"15684_CR32","doi-asserted-by":"publisher","first-page":"549843","DOI":"10.1155\/2015\/549843","volume":"2015","author":"YX Song","year":"2015","unstructured":"Song YX, Huang XZ, Gao P, Sun JX, Chen XW, Yang YC, et al. Clinicopathologic and prognostic value of serum carbohydrate antigen 19\u2009\u2013\u20099 in gastric cancer: A Meta-Analysis. Dis Markers. 2015;2015:549843. https:\/\/doi.org\/10.1155\/2015\/549843.","journal-title":"Dis Markers"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15684-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15684-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15684-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:32:57Z","timestamp":1772796777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15684-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15684"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15684-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Dokuz Eyl\u00fcl University Ethics Committee, with a waiver of informed consent due to the retrospective design and was conducted in accordance with the Declaration of Helsinki (decision number 2024\/42\u2009\u2212\u200913, 18.12.2024).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"325"}}